Tolerion

Tolerion is a clinical-stage biopharmaceutical company with a product portfolio built around our novel antigen-specific immune tolerance induction platform. Our first three named product candidates, one in late stage clinical trials, address autoimmune disorders with candidates invented with our proprietary platform. We engineer product candidates that restore balance in autoimmune conditions in which self-antigens (or “autoantigens”) incite a destructive immune response. This approach has the important benefits of targeting the root of the pathogenic immune response without impairing healthy immune function more broadly. This affords significant efficacy and safety advantages relative to other approaches in development.